Wockhardt

Wockhardt applies to seek USFDA nod for ‘miracle’ antibiotic Zaynich

The Mumbai-based company is eyeing a US launch in FY27, marking a pivotal moment for Indian pharma innovation.

Drug maker Wockhardt rallies over 9 percent as White House exempts pharma imports from nations with trade pacts

While announcing the pharma tariffs, Trump did not specify if the levies would apply over and above the existing tariffs as defined with trade agreements with EU and Japan, and the UK.

Wockhardt shares rally over 5 percent after Zaynich used to treat pan-drug resistant infection

Wockhardt shared the details of a successful use of Zaynich in treating an infection resistant to all available antibiotics in America.

Stocks to Watch Today: DMart, NCC, Kolte Patil, VIP Industries, Sula Vineyards, Wockhardt, Akzo Nobel, Gland Pharma, Travel Food Services in focus on 14 July

Stocks to watch, 14 July: Stocks like Avenue Supermarts, NCC, Kolte-Patil Developers, VIP Industries, Sula Vineyards, Wockhardt, Akzo Nobel India, Gland Pharma, and Travel Food Services will be in focus on July 14.

Wockhardt to exit US generic pharma segment to unlock capital for high-impact areas

Continuing US generic operations would detract company from innovation agenda, says Wockhardt

Wockhardt shares jump 8% amid high trading volumes, pharma stock extends gains to 45% in one month

Wockhardt share price: The sharp rise in the share price comes on the back of high trading volumes, with over 35 lakh shares worth around Rs 640 crore being involved in active trade in the first three trading hours of June 18.

Trade Spotlight: How should you trade CDSL, Manappuram Finance, Wockhardt, HDFC Life Insurance, GSK Pharma and others on June 2?

The market is expected to trade with a positive bias, albeit within a likely rangebound zone. Below are some short-term trading ideas to consider.

Wockhardt shares jump 7% as net loss narrows to Rs 45 crore in Q4FY25

Wockhardt slashed its quarterly net loss to Rs 45 crore, boosted by revenue growth and a return to operational profitability.

Wockhardt Zaynich succeeds in third compassionate use, shares rise while tariff talk keeps pharma subdued

Investigational antibiotic 'Zaynich' was successful in curing a severe drug-resistant infection in a 15-year old cancer patient in US.

Wockhardt returns to the black with Rs 14 crore net profit in Q3, revenue rises 3%

Its revenue from operations during the reported quarter stood at Rs 721 crore. This marks a rise of nearly 3 percent from the Rs 701 crore revenue from operations reported in Q3 of FY24.

Trade Spotlight: How should you trade Tata Motors, Larsen and Toubro, Amber Enterprises, Concord Biotech, Wockhardt, and others on February 5?

The bullish sentiment is expected to sustain with the VIX reaching a one-month low. Below are some trading ideas for the near term.

Wockhardt shares up 10% after Zaynich achieves 96.8% efficacy in Phase III study

Wockhardt's Zaynich, an investigational antibiotic, has been under evaluation for its efficacy in treating complicated urinary tract infections.

Wockhardt shares rally 5% after Indian drug regulator approves Pneumonia antibiotic

Central Drugs Standard Control Organization (CDSCO) approved antibiotic Nafithromycin, sold under Miqnaf brand, as a new treatment for community-acquired bacterial Pneumonia (CABP) in adults.

Stocks to Watch Today: Bharti Airtel, Hero MotoCorp, Biocon, Wockhardt, RITES, DMart, V2 Retail, Bank of Maharashtra in focus on 3 January

Stocks To Watch Today, Jan 3: Stocks like Capital Small Finance Bank, Avenue Supermarts, Hindustan Zinc, MOIL, Varun Beverages, Indian Railway Finance Corporation, NHPC, Axiscades Technologies,Honasa Consumer, Pricol, Allcargo Logistics, PB Fintech, Swan Energy, Gujarat Toolroom, and Citichem India will be in focus on January 3.

Trade Spotlight: How should you trade HDFC Life, HUL, Piccadilly Agro, Jindal Photo, Wockhardt, SRM Contractors, and others on Tuesday?

The market is expected to consolidate further before potentially entering a fresh leg of upward movement. Below are some trading ideas for the near term.

Wockhardt rises 10% after antibiotic Zaynich, undergoing clinical trials, facilitates in a liver transplant

Habil Khorakiwala, Chairman of Wockhardt had previously said that once the trials are complete, the company will seek necessary regulatory approvals and hope to be in the market 'some time in 2026'.

Wockhardt shares rise 2% as Q2FY25 net loss narrows to Rs 16 crore

International business now contributes 77% to Wockhardt's revenue, with biosimilars clocking 30% on year growth in emerging markets.